According to these findings, it could be implied that in patients with advanced-stage prostate cancer, altered levels of IL-6 may have a significant role in the Rictor signaling cascade to promote cancer cell survival through the AKT and PKCα pathways. This evidence concerns the gene IL6 and prostate cancer.